Dr. Willmar Schwabe India has acquired Sanat Products Ltd.
Dr. Willmar Schwabe India, a subsidiary of the German Dr. Willmar Schwabe Group, has acquired Sanat Products Ltd.
Dr. Willmar Schwabe India is engaged in the manufacturing of homeopathic medicines, herbal medicines, specialty formulations and cosmetic products. Dr. Willmar Schwabe Group, based in Germany, is present on five continents. The Schwabe Group comprises several different affiliated companies in the pharmaceutical and health industry. All of the companies within the group focus on plants as the basis for developing their products.
Founded in 1984, Sanat Products Ltd. is a leading manufacturer, supplier and exporter of herbal extracts, ethical products and consumer products. The herbal extracts division (HED) is engaged in the extracting and marketing of standardized herbal extracts to meet the needs of the pharmaceutical, cosmetic, ayurvedic and food industries. The ethical products division (EPD) – prescription-based drugs – offers more than 25 products across a therapeutic mix covering significant chronic and acute segments. These products include dental, oncology, gynecology, diabetes, cardiovascular diseases, dermatology and pain management. The consumer products division (CPD) offers nutraceuticals under brands such as Sunova Bioslim, Sunova Spirulina, Sunova Dr. Shugar, Sunova Curcumin, Uplat and Turmix.
Oaklins’ team in India advised the buyer in this transaction.
Talk to the deal team
Oaklins YES Securities
Groupe Nature acquires Winco
Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.Learn more
Shield Therapeutics has raised funds
Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.Learn more